TABLE 2.
Predicted WTA structures of various staphylococcal strains
| Species/strain | WTA type (glycosylation) | Anti-WTA IgG-mediated C3 depositionb | Reference or source |
|---|---|---|---|
| S. aureus RN4220 | RboP (α- and β-GlcNAc) | ○ | 13 |
| S. aureus USA300 | RboP (α- and β-GlcNAc) | ○ | This study |
| S. aureus COL | RboP (α- and β-GlcNAc) | ○ | This study |
| S. aureus MW2 | RboP (α- and β-GlcNAc) | ○ | 14 |
| S. aureus Becker | RboP (β-GlcNAc) | ○ | This study |
| S. aureus Reynolds | RboP (β-GlcNAc) | ○ | This study |
| S. aureus JL022 | RboP (β-GlcNAc) | ○ | This study |
| S. aureus M | RboP (β-GlcNAc) | ○ | This study |
| S. aureus Wright | RboP (β-GlcNAc) | ○ | This study |
| S. aureus Smith diffuse | RboP (β-GlcNAc) | ○ | This study |
| S. aureus Lowenstein | RboP (unknowna) | X | Unknown |
| S. aureus PS187 | GroP (α-GalNAc) | X | 12 |
| S. epidermidis ATCC 14990 | GroP (α-Glc, α-GlcNAc) | X | 32 |
a
Most likely produces a nonglycosylated RboP WTA.
b
○, deposition; X, no deposition.